trial · primary record
Nivolumab
Medulloblastoma
| Phase | Phase 2 |
|---|---|
| Status | TERMINATED |
| Sponsor | Unknown |
| Enrolment | 136 |
| Primary completion | 2025-06-23 |
| Primary endpoint | Disease Control Rate (Complete Response (CR) + Partial Response (PR) or Durable Stable Disease (SD) for 6 Months Measured in a Variety of Recurrent Refractory Primary Central Nervous System Tumors Reported With Standard Deviation |
| Registry ID | NCT03173950 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:33:13.495Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03173950
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.